Status:
COMPLETED
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
- Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Exclusion
- Prior systemic therapy for lung cancer
- Symptomatic Central Nervous System (CNS) metastases
- History of autoimmune disease
Key Trial Info
Start Date :
December 13 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 17 2017
Estimated Enrollment :
1351 Patients enrolled
Trial Details
Trial ID
NCT01450761
Start Date
December 13 2011
End Date
May 17 2017
Last Update
July 8 2020
Active Locations (225)
Enter a location and click search to find clinical trials sorted by distance.
1
Genesis Cancer Center
Hot Springs, Arkansas, United States, 71913
2
Sutter Medical Center
Auburn, California, United States, 95602
3
UCSD Moores Cancer Center
La Jolla, California, United States, 92093
4
University Of Colorado Cancer Center
Aurora, Colorado, United States, 80045